Company intelligence / Profile preview
NED Biosystems
Cambridge, Massachusetts, United Statesnedbiosystems.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
NED-170 has allowed the first 27 observational patients (mostly heavily pre-treated, late-stage IV) extended survival with some achieving and sustaining no evidence of disease[5]. A Phase 1b/2 clinical trial for NED-170 is being conducted in collaboration with the Institute for Systems Biology[3].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Repurposed oral agentsnutraceuticals
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Institute for Systems Biology (ISB)
Beyond the preview
Go deeper on NED Biosystems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NED Biosystems.